Functional testing for BRCA1 and BRCA2

$0P50FY2002CANIH

Dana-Farber Cancer Institute, Boston MA

Investigators

Linked publications & trials

Paper 35482127 Paper 34740923 Paper 30165125 Paper 29437794 Paper 29203461 Paper 29079937 Paper 28976793 Paper 27599144 Paper 27154787 Paper 26981373 Paper 26957554 Paper 26868124 Paper 26658964 Paper 26644530 Paper 26578779 Paper 26169615 Paper 25964252 Paper 25940996 Paper 25862352 Paper 25757412 Paper 25752389 Paper 25749734 Paper 25607768 Paper 25534386 Paper 25342443 Paper 25184681 Paper 25158653 Paper 25092866 Paper 25085806 Paper 25034439 Paper 24888816 Paper 24859938 Paper 24756187 Paper 24516021 Paper 24500108 Paper 24485702 Paper 24319068 Paper 24122390 Paper 24113744 Paper 24085845 Paper 23912961 Paper 23861913 Paper 23829891 Paper 23813304 Paper 23777977 Paper 23770079 Paper 23741308 Paper 23689072 Paper 23657012 Paper 23613961 Paper 23609472 Paper 23580068 Paper 23568001 Paper 23306204 Paper 23297033 Paper 23264681 Paper 23085768 Paper 23025714 Paper 23015398 Paper 23011924 Paper 22976474 Paper 22941538 Paper 22896036 Paper 22886304 Paper 22863008 Paper 22843421 Paper 22802530 Paper 22722202 Paper 22722201 Paper 22710706 Paper 22674478 Paper 22652104 Paper 22623710 Paper 22622809 Paper 22608084 Paper 22608083 Paper 22588880 Paper 22585699 Paper 22576213 Paper 22550168 Paper 22544643 Paper 22532574 Paper 22492774 Paper 22454379 Paper 22414675 Paper 22392042 Paper 22172014 Paper 22144471 Paper 22099046 Paper 22076478 Paper 22042860 Paper 22037872 Paper 21953249 Paper 21900114 Paper 21876152 Paper 21844186 Paper 21830014 Paper 21822287 Paper 21809116 Paper 21798043

Abstract

This proposal aims to apply recent advances in the understanding of BRCA1 and BRCA2 function to the clinical problem of uncharacterized variant alleles of BRCA1 and BRCA2. As more women have their BRCA1 and BRCA2 genes sequenced, distinguishing between true- disease causing alleles and benign polymorphisms has become a critical clinical issue. At present, no assay exists that reflects the tumor suppression activity of these genes. In Specific Aim 1 we propose to develop an assay based on the ability of various alleles to complement defects in radiation resistance and DNA double strand break repair in a BRCA1-BRCA2 demonstrate the haploinsufficiency. If this is the case, we will investigate the possibility that any much phenotype could form the basis for an assay aimed at distinguishing benign from disease-linked alleles of BRCA1 and BRCA2.

View original record on NIH RePORTER →